MACROGENICS INC
MGNX · XNASCIK 1125345fmd_0WNAW68ERBY4BH4RQ3602CYNTNManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Sep 30, 2026, 60 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 92 | 158 | 60 | 64 | 105 | 77 | 152 | 59 | 150 | 150 |
| Cost of revenue | – | – | – | 0 | 0 | 3 | 3 | 1 | 1 | 0 |
| Gross profit | – | – | – | 64 | 105 | 75 | 149 | 58 | 149 | 150 |
| Research and development | 122 | 147 | 191 | 195 | 193 | 215 | 207 | 167 | 177 | 147 |
| Operating income | (60) | (22) | (171) | (177) | (131) | (203) | (121) | (168) | (111) | (73) |
| Interest expense | – | – | – | – | – | 0 | 0 | 1 | 1 | 9 |
| Other non-operating income (expense) | 2 | 3 | (0) | 25 | 1 | 1 | 2 | 10 | 9 | 6 |
| Income before taxes | – | – | – | – | – | – | (120) | (9) | (66) | (75) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | (1) |
| Net income from continuing operations | – | – | – | – | – | – | (120) | (9) | (67) | (75) |
| Net income | (59) | (20) | (171) | (152) | (130) | (202) | (120) | (9) | (67) | (75) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |